公开(公告)号：US10925892B2

公开(公告)日：2021-02-23

申请号：US16281316

申请日：2019-02-21

Applicant: Novartis AG

Inventor： Howard Allen Ketelson ,  James W. Davis ,  Rekha Rangarajan

IPC: A61K31/736 ,  A61P27/02 ,  A61K9/00 ,  A61K9/107 ,  A61K47/14 ,  A61K47/24 ,  B01F17/00 ,  A61K47/02 ,  A61K47/10

Abstract: The present invention is directed to a lipid-based ophthalmic emulsion. The emulsion has an increased amount of a mucoadhesive galactomannan polymer that promotes a long-lasting protection against desiccation and moisture retention.

公开(公告)号：US20170136057A1

公开(公告)日：2017-05-18

申请号：US15421513

申请日：2017-02-01

Applicant: Novartis AG

Inventor： James W. Davis ,  Howard Allen Ketelson ,  Elaine E. Campbell ,  David L. Meadows ,  Rekha Rangarajan

IPC: A61K31/736 ,  A61K47/10 ,  A61K47/26 ,  A61K47/02 ,  A61K31/728 ,  A61K9/00

CPC classification number: A61K31/736 ,  A61K9/0048 ,  A61K31/728 ,  A61K47/02 ,  A61K47/10 ,  A61K47/26 ,  A61K47/32 ,  A61K47/36

Abstract: The present invention relates to artificial tear compositions and ophthalmic compositions suitable for drug delivery. In one embodiment of the present invention, the compositions comprise a galactomannan polymer such as guar or hydroxypropyl guar, hyaluronic acid, and a cis-diol such as sorbitol. In a preferred embodiment, the compositions also comprise a borate compound.

公开(公告)号：US20140364422A1

公开(公告)日：2014-12-11

申请号：US14468243

申请日：2014-08-25

Applicant: NOVARTIS AG

Inventor： David L. Meadows ,  Howard Allen Ketelson ,  Jang-Shing Chiou ,  James W. Davis

IPC: A61K47/44 ,  A61K47/34 ,  A61K47/40 ,  A61K47/18 ,  A61K31/335 ,  A61K31/551

CPC classification number: A61K47/44 ,  A61K9/0048 ,  A61K9/08 ,  A61K31/335 ,  A61K31/551 ,  A61K47/02 ,  A61K47/186 ,  A61K47/34 ,  A61K47/36 ,  A61K47/40

Abstract: The present invention is an aqueous pharmaceutical composition that includes an ionized therapeutic agent, an ionic component and guar gum. The guar gum is present in the composition a concentration sufficient to limit interactions between the ionized therapeutic agent and the ionic component thereby imparting stability to the composition. The composition is preferably at or near physiologic pH. The aqueous pharmaceutical composition has been found particularly useful as an aqueous ophthalmic, otic or nasal composition. The pharmaceutical composition, due to its characteristics, is particularly suitable as an ophthalmic composition.

Abstract translation: 本发明是一种水性药物组合物，其包含电离治疗剂，离子组分和瓜耳胶。 瓜尔胶在组合物中存在足以限制电离治疗剂和离子组分之间的相互作用的浓度，从而赋予组合物稳定性。 组合物优选处于或接近生理pH。 已经发现水性药物组合物特别可用作眼科，耳鼻喉或鼻腔组合物。 由于其特性，药物组合物特别适合作为眼用组合物。

公开(公告)号：US20190255096A1

公开(公告)日：2019-08-22

申请号：US16281316

申请日：2019-02-21

Applicant: Novartis AG

Inventor： Howard Allen Ketelson ,  James W. Davis ,  Rekha Rangarajan

IPC: A61K31/736 ,  A61K9/00 ,  A61K9/107 ,  A61K47/14 ,  A61K47/24 ,  A61P27/02

Abstract: The present invention is directed to a lipid-based ophthalmic emulsion. The emulsion has an increased amount of a mucoadhesive galactomannan polymer that promotes a long-lasting protection against desiccation and moisture retention.